About Mersana
Mersana is a company based in Cambridge (United States) founded in 2001 was acquired by Day One in November 2025.. Mersana has raised $136.23 million across 9 funding rounds from investors including Day One, Takeda Pharmaceuticals and 180 Degree Capital. The company has 102 employees as of December 31, 2024. Mersana offers products and services including Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056. Mersana operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 102 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mersana Therapeutics, Inc.
-
Annual Revenue
$40.5 M9.88as on Dec 31, 2024
-
Net Profit
$-69.19 M59.69as on Dec 31, 2024
-
EBITDA
$-71.71 M57.68as on Dec 31, 2024
-
Total Equity Funding
$136.23 M (USD)
in 9 rounds
-
Latest Funding Round
$33.1 M (USD), Series C
Jun 16, 2016
-
Investors
Day One
& 11 more
-
Employee Count
102
as on Dec 31, 2024
-
Acquired by
Day One
(Nov 13, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mersana
Mersana is a publicly listed company on the NASDAQ with ticker symbol MRSN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mersana
Mersana offers a comprehensive portfolio of products and services, including Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing cytotoxic antibody-drug conjugates for cancer.
Platform for creating immunostimulatory antibody-drug conjugates targeting cancer.
Antibody-drug conjugate in development for cancer treatment applications.
Experimental ADC aimed at improving cancer therapy outcomes.
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Software Development Team
11 people
Product Management Team
6 people
Scientific Team
4 people
Finance and Accounting
4 people
Legal and Compliance
3 people
Human Resources and Administration
3 people
Head Team
2 people
Unlock access to complete
Funding Insights of Mersana
Mersana has successfully raised a total of $136.23M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $33.1 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series C — $33.1M
-
First Round
First Round
(01 Aug 2008)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2016 | Amount | Series C - Mersana | Valuation | Wellington | |
| Mar, 2016 | Amount | Series B - Mersana | Valuation |
investors |
|
| Mar, 2015 | Amount | Series B - Mersana | Valuation | New Enterprise Associates |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mersana
Mersana has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Day One, Takeda Pharmaceuticals and 180 Degree Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mersana
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mersana
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mersana Comparisons
Competitors of Mersana
Mersana operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mersana
Frequently Asked Questions about Mersana
When was Mersana founded?
Mersana was founded in 2001 and raised its 1st funding round 7 years after it was founded.
Where is Mersana located?
Mersana is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Mersana a funded company?
Mersana is a funded company, having raised a total of $136.23M across 9 funding rounds to date. The company's 1st funding round was a Series B of $35M, raised on Aug 01, 2008.
How many employees does Mersana have?
As of Dec 31, 2024, the latest employee count at Mersana is 102.
What is the annual revenue of Mersana?
Annual revenue of Mersana is $40.5M as on Dec 31, 2024.
What does Mersana do?
Mersana Therapeutics was founded in 2001 in Cambridge, United States, within the biotechnology sector focused on oncology. Antibody-drug conjugates are developed to target cancer cells precisely. A biodegradable polymer platform called Fleximer is employed to build these immunoconjugates, enabling delivery of anti-tumor agents directly to diseased tissues. Operations center on advancing therapies like the lead candidate XMT-1522, which addresses HER2-positive cancers.
Who are the top competitors of Mersana?
Mersana's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Mersana offer?
Mersana offers Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056.
Is Mersana publicly traded?
Yes, Mersana is publicly traded on NASDAQ under the ticker symbol MRSN.
Who are Mersana's investors?
Mersana has 12 investors. Key investors include Day One, Takeda Pharmaceuticals, 180 Degree Capital, ArrowMark Partners, and NEA.
What is Mersana's ticker symbol?
The ticker symbol of Mersana is MRSN on NASDAQ.